Prophylactic evaluation of verubecestat on disease‐ and symptom‐modifying effects in 5XFAD mice

Abstract Introduction Alzheimer's disease (AD) is the most common form of dementia. Beta‐secretase (BACE) inhibitors have been proposed as potential therapeutic interventions; however, initiating treatment once disease has significantly progressed has failed to effectively stop or treat disease. Whe...

詳細記述

書誌詳細

主要な著者:	Adrian L. Oblak, Zackary A. Cope, Sara K. Quinney, Ravi S. Pandey, Carla Biesdorf, Andi R. Masters, Kristen D. Onos, Leslie Haynes, Kelly J. Keezer, Jill A. Meyer, Jonathan S. Peters, Scott A. Persohn, Amanda A. Bedwell, Kierra Eldridge, Rachael Speedy, Gabriela Little, Sean‐Paul Williams, Brenda Noarbe, Andre Obenaus, Michael Sasner, Gareth R. Howell, Gregory W. Carter, Harriet Williams, Bruce T. Lamb, Paul R. Territo, Stacey J. Sukoff Rizzo
フォーマット:	Artigo
言語:	Inglês
出版事項:	Wiley 2022-01-01
シリーズ:	Alzheimer’s & Dementia: Translational Research & Clinical Interventions
主題:	amyloid BACE inhibitor MODEL‐AD mouse model preclinical testing
オンライン･アクセス:	https://doi.org/10.1002/trc2.12317
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!